<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051086</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0368</org_study_id>
    <nct_id>NCT04051086</nct_id>
  </id_info>
  <brief_title>Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome</brief_title>
  <acronym>ELAST7</acronym>
  <official_title>Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Williams-Beuren syndrome is a rare genetic disorder caused by a 7q11.23
      microdeletion. The phenotype associates vasculopathy (arterial stenosis, hypertension),
      dimorphism and intellectual disability. Microdeletion includes several genes: ELN encodes for
      elastin and the haplo-insufficiency (only 1 functional copy) causes vasculopathy.

      The primary objective is to quantify plasma and urinary levels of elastin peptides in
      Williams-Beuren patients and 7q11.23 micro-duplication syndrome patients in order to
      correlate the levels of these markers with the number of copies of ELN gene (proportional
      positive relationship &quot;gene copy number - circulating levels of markers) Materials and
      Methods: This prospective study will be carried out in Lyon at the &quot;Hôpital
      Femme-Mère-Enfant&quot; for 2 years. 3 groups of patients will be studied: Williams-Beuren
      patients (N=20), micro-duplication 7q11.23 syndrome patients (N=10) and healthy patients
      (N=60). Subjects will be followed for 1 day.

      Clinical examination (weight, height, blood pressure) and biological sample collection (blood
      and urine sample) will be carry out for Williams Beuren and micro-duplication 7q11.23
      patients group. A large majority of visits will be part of patients' usual care. A large part
      of patients are systematically seen in consultation once a year. For healthy group, only
      biological sample collection will be carry out. The PE concentrations will be assessed and
      compared between the three groups of patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma level of elastin peptides (PE)</measure>
    <time_frame>1 day</time_frame>
    <description>To quantify plasma level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship &quot;gene copy number - circulating levels of markers).
The primary endpoint will be assessed by measuring the blood level of PE between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary level of elastin peptides (PE)</measure>
    <time_frame>1 day</time_frame>
    <description>To quantify urinary level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship &quot;gene copy number - circulating levels of markers).
The primary endpoint will be assessed by measuring the urinary level of PE between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between blood level of PE and cardiovascular involvement in patients.</measure>
    <time_frame>1 day</time_frame>
    <description>Blood level of PE will be correlated with the presence / severity of cardiovascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between urinary level of PE and cardiovascular involvement in patients.</measure>
    <time_frame>1 day</time_frame>
    <description>Urinary level of PE will be correlated with the presence / severity of cardiovascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood level of PE in treated and untreated minoxidil patients</measure>
    <time_frame>1 day</time_frame>
    <description>Blood levels of PE in the samples of patients who participated in the minoxidil clinical trial will be compare to those of participants of this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary level of PE in treated and untreated minoxidil patients</measure>
    <time_frame>1 day</time_frame>
    <description>Urinary levels of PE in the samples of patients who participated in the minoxidil clinical trial will be compare to those of participants of this study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Williams-Beuren Syndrome</condition>
  <condition>Micro-duplication 7q11.23 Syndrome</condition>
  <condition>Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Williams Beuren</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Micro-duplication 7q11.23</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects without cardiovascular and neurological medical history.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Physical examination and Urine and blood samples</intervention_name>
    <description>Only one visit for each participant : A large majority of visits will be part of patients' usual care
Medical examination : birth, weight, gender, blood pressure, medical history
Urine and blood samples</description>
    <arm_group_label>Micro-duplication 7q11.23</arm_group_label>
    <arm_group_label>Williams Beuren</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Urine and blood samples</intervention_name>
    <description>Only one visit for each participant
Medical history
Urine and blood samples</description>
    <arm_group_label>Healthy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : from 3 months to 60 years old

          -  Williams Beuren group : Diagnosis confirmed with FISH

          -  Micro-duplication 7q11.23 group : Diagnosis confirmed with CGHarray

          -  Healthy Group : no cardiovascular and neurological medical history

          -  Informed consent

        Exclusion Criteria:

          -  No social insurance

          -  Subject under judicial protection

          -  Subject participating in another research including an exclusion period still in
             progress
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Massimiliano ROSSI, Dr</last_name>
    <phone>04 27 85 55 72</phone>
    <phone_ext>+33</phone_ext>
    <email>Massimiliano.rossi@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda PONS, Dr</last_name>
    <phone>04.27.85.51.43</phone>
    <phone_ext>+33</phone_ext>
    <email>linda.pons@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant - Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Massimiliano ROSSI, Dr</last_name>
      <phone>04 27 85 55 72</phone>
      <phone_ext>+33</phone_ext>
      <email>Massimiliano.rossi@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Linda PONS, Dr</last_name>
      <phone>04.27.85.51.43</phone>
      <phone_ext>+33</phone_ext>
      <email>linda.pons@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Massimiliano ROSSI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick EDERY, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien SANLAVILLE, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélia BERTHOLET-THOMAS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie PORTEFAIX, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel BOUVET, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Williams-Beuren Syndrome</keyword>
  <keyword>Micro-duplication 7q11.23 syndrome</keyword>
  <keyword>Vasculopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Williams Syndrome</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

